how does noom glp 1 work Noom's GLP-1 Companion Receives Major Update to Prepare for Noom Launches Free Version of

Since commercial patients tend to be younger and healthier than Medicare beneficiaries, early GLP-1 use is reinforcing its role as a reliable foundation for diabetes care and could be a contributing factor to rising rates of monotherapy

Yes, for short-term use in most people

Other risks include an increased likelihood of hypotension and syncope

Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

The biggest external factor is regulatory: compounded GLP-1 availability is in transition under FDA enforcement, and anyone starting a program in June 2026 should understand what that means for supply continuity